Inhibitory Effect of Lomerizine, a Diphenylpiperazine Ca2+ -Channel Blocker, on Ba2+ Current Through Voltage-Gated Ca2+ Channels in PC 12 Cells

Total Page:16

File Type:pdf, Size:1020Kb

Inhibitory Effect of Lomerizine, a Diphenylpiperazine Ca2+ -Channel Blocker, on Ba2+ Current Through Voltage-Gated Ca2+ Channels in PC 12 Cells Inhibitory Effect of Lomerizine, a Diphenylpiperazine Ca2+ -Channel Blocker, on Ba2+ Current through Voltage-Gated Ca2+ Channels in PC 12 Cells Tomokazu Watanol, Hideaki Hara2,* and Takayuki Sukamoto2 1 Department of Pharmacology, New Drug Discovery Research Laboratory, Kanebo Ltd., 1-5-90 Tomobuchi-cho,of Pharmacology, Miyakojima-ku, New Drug Osaka R & 534,D Laboratory, Japan2Department Kanebo Ltd., 1-5-90 Tomobuchi-cho, Miyakojima-ku, Osaka 534, Japan Received July 8, 1997 Accepted August 22, 1997 ABSTRACT-We investigated the effect of lomerizine, an anti-migraine drug, on the Ba2+ current through voltage-gated Ca2+ channels in rat pheochromocytoma (PC12) cells using a whole-cell voltage-clamp tech nique. Lomerizine inhibited the Ba2+ current with an IC50 value of 1.9 ƒÊM. Lomerizine and nicardipine were > 4 times more potent than flunarizine, diltiazem, verapamil and dimetotiazine. The time course of inactivation induced by lomerizine was similar to that induced by nicardipine and flunarizine. These data indicate that lomerizine may inhibit the Ca2+ channel in a similar manner to nicardipine and flunarizine, and its potency is almost equal to that of nicardipine. Keywords: Lomerizine , Voltage-gated Ca2+ channel, PCl2 cell Calcium channel blockers are mainly divided into three Bio Medical, Kyoto) containing 7° fetal bovine serum types, namely, 1,4-dihydropyridine, phenylalkylamine (Moregate, Melbourne, Australia), 7% heat-inactivated and benzothiazepine types, from their structure (1). horse serum (Gibco, Grand Island, NY, USA), 2 MM L Lomerizine, 1-[bis(4-fluorophenyl)methyl]-4-(2,3,4 glutamine (Wako, Osaka) and 50 pg/ml gentamicin sul trimethoxybenzyl)piperazine dihydrochloride has been fate (Wako) at 37C in an atmosphere of 5% CO2. They reported to inhibit [3H]nitrendipine binding to synapto were then plated onto collagen-coated glass slides. After some membranes in guinea pig cerebral cortex (2) and an additional 2 to 3 days in culture, the cells were used for canine aorta (3), to inhibit the voltage-gated Ca 2+ current the following experiments. in rat hippocampal pyramidal neurons (4) and to reduce Membrane potentials and currents were measured the number of migraine attacks in patients with migraine using whole-cell recordings and improved patch-clamp (5, 6). Thus, lomerizine is regarded as a new class of cal techniques (8). The cells were continuously superfused cium channel blocker with different structure from the with an extracellular solution containing 140 mM NaCI, representative calcium channel blockers as described the 5.4 mM KCI, 1.8 mM CaC12and 10 mM 2-[4-(2-hydroxy above. However, the pharmacological profile of lomeri ethyl)-1-piperazinyl]ethanesulphonic acid (HEPES, zine has not yet been fully clarified in comparison with Wako), pH adjusted to 7.4 with NaOH. The heat that of existing calcium channel blockers. Therefore, we polished patch pipettes each had a tip resistance of about investigated the effect of lomerizine on the Ba2+ current 5 MQ when filled with an intracellular solution containing through the voltage-gated Ca 2+ channel in rat 150 mM CsCl, 10 mM HEPES and 5 mM O,O'-bis(2 pheochromocytoma (PC12) cells and compared it with aminoethyl)ethyleneglycol-N,N, N, N'tetraacetic acid those of various other types of calcium channel blockers (EGTA, Wako), pH adjusted to 7.3 with CsOH. Mem and that of dimetotiazine, an anti-migraine drug. brane potentials were controlled by a voltage-clamp am PC 12 cells (Riken Cell Bank, Ibaraki) were prepared as plifier (Axopatch 200A; Axon, Foster City, CA, USA). previously described (7). In brief, PC12 cells were cul Membrane currents were acquired on-line and analyzed tured in Dulbecco's Modified Eagle's Medium (Nikken later by a computer (PC-5/120; Inter Medical, Nagoya) using pCLAMP6 software (Axon). As Ca2+ channels are * To whom correspondence should be addressed . more permeable to Ba2+ than to Ca2+ (9), extracellular CaC12 was replaced with BaC12 (10.8 mM) to obtain a steady-state blockade was obtained by 60 sec after the large inward Ba2+ current permeating through voltage start of the superfusion (Fig. 1A) at concentrations of gated Ca2+ channels. Compensation was made for series 0.1-10 ,uM. This effect was similar to those produced by resistance, and electrical signals were filtered at 5 kHz. nicardipine, flunarizine and dimetotiazine (data not The inward current was activated by a depolarizing step shown). On the other hand, the steady-state blocking to +10 mV from a holding potential of 60 mV. The effect of diltiazem reached a steady state level at 120 sec experiments were performed at approximately 361C using after the start of the superfusion at concentrations of a TC2b;p bipolar temperature controller (Bioptechs, Inc., 1-100 ,uM in most of the cells examined (Fig. 1B). The Butler, PA, USA). The IC50 value for each drug in in profile of the inhibition produced by verapamil was simi hibiting Ba2+ current was calculated by Probit analysis. lar to that seen with diltiazem (data not shown). There Lomerizine 2HC1 (Kanebo, Osaka); nicardipine HC1 fore, for routine assessment of the typical inhibition flunarizine 2HCl, (±)-verapamil, diltiazem HCl (Sigma, produced by each drug and to derive the concentration St. Louis, MO, USA); and dimetotiazine mesylate inhibition curves, the effects on the Ba2+ current of (Shionogi, Osaka) were first dissolved in dimethyl sulf lomerizine, nicardipine, flunarizine and dimetotiazine in oxide (DMSO, Wako) and added to extracellular solu concentrations of 0.1-10 ,uM were tested at 60 sec after tions so that the final concentration of DMSO was the beginning of their superfusion, whereas the effects of <<0.1%. diltiazem and verapamil in concentrations of 1-100 ,uM Figure 1 shows typical records of the blocking effect of were tested at 120 sec. lomerizine and diltiazem on the Ba2+ current through Figure 2 shows typical examples of the inhibitory voltage-gated Ca 21 channels in PC 12 cells. The inhibition effects of lomerizine, nicardipine, flunarizine, diltiazem, produced by lomerizine was time-dependent: it was first verapamil and dimetotiazine on the Ba2+ current. Cur observed at 20 sec after the start of the superfusion, and a rent traces obtained just before (Control) and after the Fig. 1. Time-dependency of inhibition by lomerizine and diltiazem of Ba2+ current in PC12 cells. The Ba2+ current was acti vated by a 200 msec depolarizing step pulse from -60 mV to + 10 mV every 10 sec. A: Current traces recorded 60 sec before (-60), just before (0) and 10-70 sec after the application of lomerizine (10 PM). B: Current traces recorded 60 sec before (-60), just before (0) and 10-130 sec after the application of diltiazem (10 pM). Fig. 2. Effects of lomerizine, nicardipine, flunarizine, diltiazem, verapamil and dimetotiazine on Ba2+ current in PC12 cells. The Ba2+ current was activated by a 200-msec depolarizing step pulse from -60 mV to +10 mV every 10 sec. Panels for lomerizine (A), nicardipine (B), flunarizine (C) and dimetotiazine (F) show superimposed the current traces from just before (control) and 60 sec after the application of the doses shown. Those for diltiazem (D) and verapamil (E) show superimposed current traces from just before (control) and 120 sec after the application of the doses shown. superfusion of a given drug at various concentrations rent. In a preliminary experiment, the current-voltage (between 0.1 and 100 pM) are superimposed. Each of the (I-V) relationship exhibited a bell-shape, peaking at + 10 drugs concentration-dependently inhibited the Ba2+ cur mV, as has been previously reported (9, 10); and lomeri zine did not affect the I-V relationship. Therefore, we both L-type and T-type Ca 2+ currents in a hippocampal investigated the time-dependency and concentration CA1 pyramidal single neuron (4) and does not have any response relationship with a depolarizing step to +10 affinity for N-type Ca2+ channels in a [1211]w-conotoxin mV. binding study using rat cortical membranes (unpublished Figure 3 shows the concentration-response relationship observation, H. Hara et al.). for these drugs. The IC50 values (with 95010 confidence In this experiment, lomerizine concentration-depend limits) for lomerizine, nicardipine, flunarizine, diltiazem ently inhibited high-voltage activated inward Ba2+ cur and verapamil were 1.9 (1.1-3.9), 2.0 (0.86-6.2), 7.9 rents. The time course (inhibition pattern) of the effect of (3.1 52), 13.0 (6.7 27) and 10.4 (5.1 21) pM, respec lomerizine on Ba2+ current was similar to those of tively. Dimetotiazine produced only an approximately nicardipine and flunarizine, but different from those of 40% inhibition at a concentration of 10 pM (the highest diltiazem and verapamil. Maximal steady state inhibition concentration used). Lomerizine and nicardipine were induced by lomerizine, nicardipine or flunarizine was ob both > 4 times more potent than the other three calcium served faster than that induced by diltiazem or verapamil. channel blockers and dimetotiazine. These data indicate that the mode of action of lomerizine We examined the effect of lomerizine on Ca2+ channels in inhibiting L-type Ca 2+ channels may be similar to that in PC12 cells and compared the effect with those of four of nicardipine and flunarizine and different from that of other calcium channel blockers and with that of diltiazem and verapamil. dimetotiazine. PC12 cells have been used widely in studies Each of the 1,4-dihydropyridines studied here, diltia requiring a neuron-like clone cell-line. The Ba2+ current zem and verapamil, interacts with a specific receptor in PC12 cells was classified as an example of L-type domain found on a large (about 165 kD) membrane Ca 21 channel activity by Tsien et al. (11). Although un spanning protein that constitutes a substantial portion differentiated PC 12 cells express predominantly L-type of the L-type, voltage-gated Ca 2+ channel (14).
Recommended publications
  • Perception of Facial Expressions in Social Anxiety and Gaze Anxiety
    The Pegasus Review: UCF Undergraduate Research Journal (URJ) Volume 9 Issue 1 Article 6 2016 Perception of Facial Expressions in Social Anxiety and Gaze Anxiety Aaron Necaise University of Central Florida, [email protected] Part of the Psychology Commons Find similar works at: https://stars.library.ucf.edu/urj University of Central Florida Libraries http://library.ucf.edu This Article is brought to you for free and open access by the Office of Undergraduate Research at STARS. It has been accepted for inclusion in The Pegasus Review: UCF Undergraduate Research Journal (URJ) by an authorized editor of STARS. For more information, please contact [email protected]. Recommended Citation Necaise, Aaron (2016) "Perception of Facial Expressions in Social Anxiety and Gaze Anxiety," The Pegasus Review: UCF Undergraduate Research Journal (URJ): Vol. 9 : Iss. 1 , Article 6. Available at: https://stars.library.ucf.edu/urj/vol9/iss1/6 Necaise: Perception of Facial Expressions Social Anxiety & Gaze Anxiety Published Vol. 9.1: 40-47 October 19th, 2017 THE UNIVERSITY OF CENTRAL FLORIDA UNDERGRADUATE RESEARCH JOURNAL Analysis of the Pathomechanism and Treatment of Migraines Related to the Role of the Neuropeptide CGRP By: Marvi S. Qureshi Faculty Mentor: Dr. Mohtashem Samsam UCF Burnett School of Biomedical Sciences ABSTRACT: Migraines are a type of headache that specifically act on only one side of the head, although about 30% of patients with migraines may experience a bilateral headache. Migraines are brain disorders that typically involve issues of sensory processing taking place in the brainstem. Possible causation has been linked to blood vessels, blood flow, and oxygen levels in the brain.
    [Show full text]
  • ERJ-01090-2018.Supplement
    Shaheen et al Online data supplement Prescribed analgesics in pregnancy and risk of childhood asthma Seif O Shaheen, Cecilia Lundholm, Bronwyn K Brew, Catarina Almqvist. 1 Shaheen et al Figure E1: Data available for analysis Footnote: Numbers refer to adjusted analyses (complete data on covariates) 2 Shaheen et al Table E1. Three classes of analgesics included in the analyses ATC codes Generic drug name Opioids N02AA59 Codeine, combinations excluding psycholeptics N02AA79 Codeine, combinations with psycholeptics N02AA08 Dihydrocodeine N02AA58 Dihydrocodeine, combinations N02AC04 Dextropropoxyphene N02AC54 Dextropropoxyphene, combinations excluding psycholeptics N02AX02 Tramadol Anti-migraine N02CA01 Dihydroergotamine N02CA02 Ergotamine N02CA04 Methysergide N02CA07 Lisuride N02CA51 Dihydroergotamine, combinations N02CA52 Ergotamine, combinations excluding psycholeptics N02CA72 Ergotamine, combinations with psycholeptics N02CC01 Sumatriptan N02CC02 Naratriptan N02CC03 Zolmitriptan N02CC04 Rizatriptan N02CC05 Almotriptan N02CC06 Eletriptan N02CC07 Frovatriptan N02CX01 Pizotifen N02CX02 Clonidine N02CX03 Iprazochrome N02CX05 Dimetotiazine N02CX06 Oxetorone N02CB01 Flumedroxone Paracetamol N02BE01 Paracetamol N02BE51 Paracetamol, combinations excluding psycholeptics N02BE71 Paracetamol, combinations with psycholeptics 3 Shaheen et al Table E2. Frequency of analgesic classes prescribed to the mother during pregnancy Opioids Anti- Paracetamol N % migraine No No No 459,690 93.2 No No Yes 9,091 1.8 Yes No No 15,405 3.1 No Yes No 2,343 0.5 Yes No
    [Show full text]
  • Potential Mechanisms of Prospective Antimigraine Drugs: a Focus on Vascular (Side) Effects
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Pharmacology & Therapeutics 129 (2011) 332–351 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate Editor: John Fozard Potential mechanisms of prospective antimigraine drugs: A focus on vascular (side) effects Kayi Y. Chan a, Steve Vermeersch b, Jan de Hoon b, Carlos M. Villalón c, Antoinette MaassenVanDenBrink a,⁎ a Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands b Center for Clinical Pharmacology, University Hospitals Leuven, Campus Gasthuisberg, (K.U. Leuven), Leuven, Belgium c Departamento de Farmacobiología, Cinvestav-Coapa, Czda. de los Tenorios 235, Col. Granjas-Coapa, Deleg. Tlalpan, C.P. 14330, México D.F., Mexico article info abstract Available online 2 December 2010 Currently available drugs for the acute treatment of migraine, i.e. ergot alkaloids and triptans, are cranial vasoconstrictors. Although cranial vasoconstriction is likely to mediate—at least a part of—their therapeutic Keywords: effects, this property also causes vascular side-effects. Indeed, the ergot alkaloids and the triptans have been Antimigraine drugs reported to induce myocardial ischemia and stroke, albeit in extremely rare cases, and are contraindicated in Neuropeptides patients with known cardiovascular risk factors. In view of these limitations, novel antimigraine drugs
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • 1-(4-Amino-Cyclohexyl)
    (19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art.
    [Show full text]
  • Current and Prospective Pharmacological Targets in Relation to Antimigraine Action
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Erasmus University Digital Repository Naunyn-Schmiedeberg’s Arch Pharmacol (2008) 378:371–394 DOI 10.1007/s00210-008-0322-7 REVIEW Current and prospective pharmacological targets in relation to antimigraine action Suneet Mehrotra & Saurabh Gupta & Kayi Y. Chan & Carlos M. Villalón & David Centurión & Pramod R. Saxena & Antoinette MaassenVanDenBrink Received: 8 January 2008 /Accepted: 6 June 2008 /Published online: 15 July 2008 # The Author(s) 2008 Abstract Migraine is a recurrent incapacitating neuro- (CGRP1 and CGRP2), adenosine (A1,A2,andA3), glutamate vascular disorder characterized by unilateral and throbbing (NMDA, AMPA, kainate, and metabotropic), dopamine, headaches associated with photophobia, phonophobia, endothelin, and female hormone (estrogen and progesterone) nausea, and vomiting. Current specific drugs used in the receptors. In addition, we have considered some other acute treatment of migraine interact with vascular receptors, targets, including gamma-aminobutyric acid, angiotensin, a fact that has raised concerns about their cardiovascular bradykinin, histamine, and ionotropic receptors, in relation to safety. In the past, α-adrenoceptor agonists (ergotamine, antimigraine therapy. Finally, the cardiovascular safety of dihydroergotamine, isometheptene) were used. The last two current and prospective antimigraine therapies is touched decades have witnessed the advent of 5-HT1B/1D receptor upon. agonists (sumatriptan and second-generation triptans), which have a well-established efficacy in the acute Keywords 5-HT. Antimigraine drugs . CGRP. treatment of migraine. Moreover, current prophylactic Noradrenaline . Migraine . Receptors treatments of migraine include 5-HT2 receptor antagonists, Ca2+ channel blockers, and β-adrenoceptor antagonists. Despite the progress in migraine research and in view of its Introduction complex etiology, this disease still remains underdiagnosed, and available therapies are underused.
    [Show full text]
  • Serotonin Receptor Knockouts: a Moody Subject David Julius* Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94143-0450
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 15153–15154, December 1998 Commentary Serotonin receptor knockouts: A moody subject David Julius* Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94143-0450 The neurotransmitter serotonin (5-hydroxytryptamine; 5-HT) receptors are expressed in a number of brain regions to which is believed to play a significant role in determining one’s serotonergic neurons project, including the hippocampus, ce- emotional state. Indeed, serotonergic synapses are sites of rebral cortex, and amygdala (11, 12). As in the case of action for a number of mood-altering drugs, including the presynaptic autoreceptors, activation of postsynaptic 5-HT1A now-legendary antidepressant Prozac (fluoxetine) (1). As a receptors leads to hyperpolarization of the neuron and the result, there has been tremendous interest in identifying consequent inhibition of neurotransmitter release. This effect molecular components of the serotonergic system, including appears to be mediated through a biochemical signaling path- cell surface receptors and transporters, and understanding way in which 5-HT1A receptors activate a G protein (Gi)- whether and how these proteins contribute to the regulation of coupled inwardly rectifying potassium channel (13, 14). mood and emotion. This quest is driven, in part, by the In light of the pharmacological evidence that 5-HT1A re- possibility that behavioral disorders, such as depression or ceptors exert negative ‘‘feedback’’ control on serotonergic anxiety, may be linked to deficits in one or more components neurons, one would predict that mice lacking this receptor of this signaling system. Such information could, in turn, focus should show elevated levels of extraneuronal serotonin, or an attention on specific targets for the development of novel increase in the amount of serotonin released after nerve drugs with which to treat psychiatric disorders.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Preventive Report Appendix
    Title Authors Published Journal Volume Issue Pages DOI Final Status Exclusion Reason Nasal sumatriptan is effective in treatment of migraine attacks in children: A Ahonen K.; Hamalainen ML.; Rantala H.; 2004 Neurology 62 6 883-7 10.1212/01.wnl.0000115105.05966.a7 Deemed irrelevant in initial screening Seasonal variation in migraine. Alstadhaug KB.; Salvesen R.; Bekkelund SI. Cephalalgia : an 2005 international journal 25 10 811-6 10.1111/j.1468-2982.2005.01018.x Deemed irrelevant in initial screening Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Amery WK. 1983 Headache 23 2 70-4 10.1111/j.1526-4610.1983.hed2302070 Deemed irrelevant in initial screening Monoamine oxidase inhibitors in the control of migraine. Anthony M.; Lance JW. Proceedings of the 1970 Australian 7 45-7 Deemed irrelevant in initial screening Prostaglandins and prostaglandin receptor antagonism in migraine. Antonova M. 2013 Danish medical 60 5 B4635 Deemed irrelevant in initial screening Divalproex extended-release in adolescent migraine prophylaxis: results of a Apostol G.; Cady RK.; Laforet GA.; Robieson randomized, double-blind, placebo-controlled study. WZ.; Olson E.; Abi-Saab WM.; Saltarelli M. 2008 Headache 48 7 1012-25 10.1111/j.1526-4610.2008.01081.x Deemed irrelevant in initial screening Divalproex sodium extended-release for the prophylaxis of migraine headache in Apostol G.; Lewis DW.; Laforet GA.; adolescents: results of a stand-alone, long-term open-label safety study. Robieson WZ.; Fugate JM.; Abi-Saab WM.; 2009 Headache 49 1 45-53 10.1111/j.1526-4610.2008.01279.x Deemed irrelevant in initial screening Safety and tolerability of divalproex sodium extended-release in the prophylaxis of Apostol G.; Pakalnis A.; Laforet GA.; migraine headaches: results of an open-label extension trial in adolescents.
    [Show full text]
  • Does Sumatriptan Cross the Blood–Brain Barrier in Animals and Man?
    J Headache Pain (2010) 11:5–12 DOI 10.1007/s10194-009-0170-y REVIEW ARTICLE Does sumatriptan cross the blood–brain barrier in animals and man? Peer Carsten Tfelt-Hansen Received: 24 August 2009 / Accepted: 27 October 2009 / Published online: 10 December 2009 Ó Springer-Verlag 2009 Abstract Sumatriptan, a relatively hydrophilic triptan, development [6, 7] or an effect on trigeminovascular nerves based on several animal studies has been regarded to be [6]. A peripheral effect on trigeminal vascular nerves was unable to cross the blood–brain barrier (BBB). In more indicated by the blocking effect of sumatriptan of neuro- recent animal studies there are strong indications that genically mediated plasma extravasation [8]. Inhibitors of sumatriptan to some extent can cross the BBB. The CNS neurogenic inflammation (NI) were, however, ineffective in adverse events of sumatriptan in migraine patients and the treatment of migraine [9] and it is thus difficult to normal volunteers also indicate a more general effect of ascribe a pivotal role for NI in migraine. In 1996 it was, sumatriptan on CNS indicating that the drug can cross the based on the effect of zolmitriptan, suggested that inhibition BBB in man. It has been discussed whether a defect in the of trigeminal neurons in the brain stem by lipophilic triptans BBB during migraine attacks could be responsible for a may play a role in the anti-migraine effect of these drugs possible central effect of sumatriptan in migraine. This and that these results offered the prospect of a third path- review suggests that there is no need for a breakdown in the ophysiological target site for triptans [10].
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Histamine and Antihistaminics Chapter 11
    Histamine and Antihistaminics Chapter 11 HISTAMINE Histamine, meaning ‘tissue amine’ (histos—tissue) is almost ubiquitously present in animal tissues and in certain plants, e.g. stinging nettle. Its pharmacology was studied in detail by Dale in the beginning of the 20th century when close parallelism was noted between its actions and the manifestations of certain allergic reactions. It was implicated as a mediator of hypersensitivity Fig. 11.1: Synthesis and degradation of histamine phenomena and tissue injury reactions. It is now MAO-Monoamine oxidase known to play important physiological roles. Histamine is present mostly within storage by Asch and Schild (1966) into H1 and H2 : those granules of mast cells. Tissues rich in histamine blocked by then available antihistamines were are skin, gastric and intestinal mucosa, lungs, liver labelled H1. Sir James Black (1972) developed and placenta. Nonmast cell histamine occurs in the first H2 blocker burimamide and confirmed brain, epidermis, gastric mucosa and growing this classification. A third H3 receptor, which regions. Turnover of mast cell histamine is slow, serves primarily as an autoreceptor controlling while that of nonmast cell histamine is fast. histamine release from neurones in brain was Histamine is also present in blood, most body identified in 1983. Though some selective H3 secretions, venoms and pathological fluids. agonists and antagonists have been produced, none has found any clinical application. Features of Synthesis, storage and destruction these 3 types of histaminergic receptor are Histamine is β imidazolylethylamine. It is compared in Table 11.1. synthesized locally from the amino acid histidine Molecular cloning has revealed yet another (H4) receptor and degraded rapidly by oxidation and methylation in 2001.
    [Show full text]